DCDebby Cheng

Debby Cheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Debby Cheng has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Amirhossein Shamsaddini

    Microbiome Analysis Center, George Mason University, Manassas, VA, USA

    1 shared publication
  • Amy Ransier

    Genome Analysis Core, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD

    1 shared publication
  • Arash Mostaghimi

    Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts

    1 shared publication
  • Aurore D. Zhang

    Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts

    1 shared publication
  • Christopher J. Thang

    Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts

    1 shared publication
  • Daniel C. Douek

    Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD

    1 shared publication

Latest Publications

  • Open Access

    Quantifying the risk of drug-associated skin hyperpigmentation relative to the general population: A national cohort study using TriNetX

    by Debby Cheng, Helen Ji, David Xiang, Christopher J. Thang, Aurore D. Zhang, Arash Mostaghimi, Yevgeniy R. Semenov, Nicholas Theodosakis

  • Human CCR6+ Th Cells Show Both an Extended Stable Gradient of Th17 Activity and Imprinted Plasticity

    by Satya P. Singh, Farhat Parween, Nithin Edara, Hongwei H. Zhang, Jinguo Chen, Francisco Otaizo-Carrasquero, Debby Cheng, Nicole A Oppenheim, Amy Ransier, Wenjun Zhu, et al.

    Th17 cells have been investigated in mice primarily for their contributions to autoimmune diseases. However, the pathways of differentiation of Th17 and related Th cells (type 17 cells) and the structure of the type 17 memory population in humans are not well understood; such understanding is critical for manipulating these cells in vivo. By exploiting differences in levels of surface CCR6, we found that human type 17 memory cells, including individual T cell clonotypes, form an elongated continuum of type 17 character along which cells can be driven by increasing RORγt. This continuum includes cells preserved within the memory pool with potentials that reflect the early preferential activation of multiple over single lineages. The phenotypes and epigenomes of CCR6+ cells are stable across cell divisions under noninflammatory conditions. Nonetheless, activation in polarizing and nonpolarizing conditions can yield additional functionalities, revealing, respectively, both environmentally induced and imprinted mechanisms that contribute differentially across the type 17 continuum to yield the unusual plasticity ascribed to type 17 cells.


  • Open Access

    Trends in oncological imaging during the COVID‐19 pandemic through the vaccination era

    by Debby Cheng, Soham Ghoshal, Ottavia Zattra, Moses Flash, Min Lang, Raymond Liu, Michael H. Lev, Joshua A. Hirsch, Sanjay Saini, Michael S. Gee, et al.

    Background: This study examines the impact that the COVID-19 pandemic has had on computed tomography (CT)-based oncologic imaging utilization.Methods: We retrospectively analyzed cancer-related CT scans during four time periods: pre-COVID (1/5/20-3/14/20), COVID peak (3/15/20-5/2/20), post-COVID peak (5/3/20-12/19/20), and vaccination period (12/20/20-10/30/21). We analyzed CTs by imaging indication, setting, and hospital type. Using percentage decrease computation and Student's t-test, we calculated the change in mean number of weekly cancer-related CTs for all periods compared to the baseline pre-COVID period. This study was performed at a single academic medical center and three affiliated hospitals.Results: During the COVID peak, mean CTs decreased (-43.0%, p < 0.001), with CTs for (1) cancer screening, (2) initial workup, (3) cancer follow-up, and (4) scheduled surveillance of previously treated cancer dropping by 81.8%, 56.3%, 31.7%, and 45.8%, respectively (p < 0.001). During the post-COVID peak period, cancer screenings and initial workup CTs did not return to prepandemic imaging volumes (-11.4%, p = 0.028; -20.9%, p = 0.024). The ED saw increases in weekly CTs compared to prepandemic levels (+31.9%, p = 0.008), driven by increases in cancer follow-up CTs (+56.3%, p < 0.001). In the vaccination period, cancer screening CTs did not recover to baseline (-13.5%, p = 0.002) and initial cancer workup CTs doubled (+100.0%, p < 0.001). The ED experienced increased cancer-related CTs (+75.9%, p < 0.001), driven by cancer follow-up CTs (+143.2%, p < 0.001) and initial workups (+46.9%, p = 0.007).Conclusions and relevance: The pandemic continues to impact cancer care. We observed significant declines in cancer screening CTs through the end of 2021. Concurrently, we observed a 2x increase in initial cancer workup CTs and a 2.4x increase in cancer follow-up CTs in the ED during the vaccination period, suggesting a boom of new cancers and more cancer examinations associated with emergency level acute care.